Abstract
The present invention pertains generally to the field of therapeutic compounds.
5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole-
2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling.
The present invention also pertains to pharmaceutical compositions comprising such
compounds, and the use of such compounds and compositions, both in vitro and in vivo,
to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the
10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes,
dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and
other conditions as described herein
5 More specifically the present invention pertains to certain N-(arylalkyl)-1H-indole-
2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling.
The present invention also pertains to pharmaceutical compositions comprising such
compounds, and the use of such compounds and compositions, both in vitro and in vivo,
to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the
10 inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes,
dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and
other conditions as described herein
| Original language | English |
|---|---|
| Patent number | WO2012117216 |
| IPC | WO2012117216 |
| Publication status | Published - 28 Feb 2011 |
